137116 20240321220207.0 10.1097/WCO.0b013e3283632da6 doi pmid:23812308 pmid pmc:PMC4196800 pmc 1350-7540 ISSN 1473-6551 ISSN altmetric:1593541 altmetric DZNE-2020-03438 English 610 Stamelou, Maria P:(DE-HGF)0 0 Corresponding author Atypical parkinsonism: an update. [S.l.] 2013 Ovid print Crossref Ovid Technologies (Wolters Kluwer Health) 2013-08-01 article DRIVER Output Types/Journal article DataCite Journal Article journal journal PUB:(DE-HGF)16 1588933458_10353 PUB:(DE-HGF) Review Article ARTICLE BibTeX JOURNAL_ARTICLE ORCID Journal Article 0 EndNote This update discusses novel aspects on genetics, diagnosis, and treatments of atypical parkinsonism published over the past 2 years.A genome-wide association study identified new genetic risk factors for progressive supranuclear palsy and new genetic conditions presenting with atypical parkinsonism have been described. The clinical criteria for diagnosis of corticobasal degeneration have been revised, and for progressive supranuclear palsy are under revision. Novel molecular techniques to identify possible biomarkers, as in other neurodegenerative disorders, have started being studied on atypical parkinsonian conditions, and although preliminary results seem promising, further studies are urgently warranted. Therapeutic trials based on disease-specific targets have shown no clinical improvement.The knowledge obtained recently on atypical parkinsonian conditions points out the major deficits in this field. With the expanding phenotypical spectrum of atypical parkinsonian conditions, the early identification of patients has become difficult. The inability of conventional methods to identify these disorders earlier and better than clinicians, and the recent failure of promising therapeutic compounds, highlight the fact that the lack of biomarkers is probably the greatest limitation for developing treatments for these disorders. Thus, current and future research in this direction will be crucial. 344 - Clinical and Health Care Research (POF3-344) G:(DE-HGF)POF3-344 POF3-344 POF III 0 Dataset connected to CrossRef, PubMed, Diagnosis, Differential MeSH Genome-Wide Association Study MeSH Humans MeSH Neuroimaging MeSH Parkinsonian Disorders: diagnosis MeSH Parkinsonian Disorders: genetics MeSH Parkinsonian Disorders: pathology MeSH Risk Factors MeSH Severity of Illness Index MeSH Supranuclear Palsy, Progressive: diagnosis MeSH Höglinger, Günter P:(DE-2719)2811373 1 Last author dzne 10.1097/wco.0b013e3283632da6 : Ovid Technologies (Wolters Kluwer Health), 2013-08-01 4 401-405 journal-article Crossref Current Opinion in Neurology 26 2013 1350-7540 10.1097/WCO.0b013e3283632da6 Vol. 26, no. 4, p. 401 - 405 PERI:(DE-600)2026967-5 4 26:4<401 - 405 401-405 Current opinion in neurology 26 2013 1350-7540 Pubmed Central http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196800 oai:pub.dzne.de:137116 VDB Deutsches Zentrum für Neurodegenerative Erkrankungen I:(DE-588)1065079516 DZNE 1 P:(DE-2719)2811373 DE-HGF Forschungsbereich Gesundheit Erkrankungen des Nervensystems G:(DE-HGF)POF3-340 G:(DE-HGF)POF3-344 G:(DE-HGF)POF3-300 Clinical and Health Care Research 0 2013 Allianz-Lizenz StatID:(DE-HGF)0410 StatID Nationallizenz StatID:(DE-HGF)0420 StatID JCR StatID:(DE-HGF)0100 StatID CURR OPIN NEUROL : 2017 DBCoverage StatID:(DE-HGF)0200 StatID SCOPUS DBCoverage StatID:(DE-HGF)0300 StatID Medline DBCoverage StatID:(DE-HGF)0310 StatID NCBI Molecular Biology Database DBCoverage StatID:(DE-HGF)0199 StatID Clarivate Analytics Master Journal List WoS StatID:(DE-HGF)0110 StatID Science Citation Index DBCoverage StatID:(DE-HGF)0150 StatID Web of Science Core Collection WoS StatID:(DE-HGF)0111 StatID Science Citation Index Expanded DBCoverage StatID:(DE-HGF)1110 StatID Current Contents - Clinical Medicine DBCoverage StatID:(DE-HGF)1050 StatID BIOSIS Previews DBCoverage StatID:(DE-HGF)1120 StatID BIOSIS Reviews Reports And Meetings IF < 5 StatID:(DE-HGF)9900 StatID I:(DE-2719)1110002 AG Höglinger 1 Translational Neurodegeneration 0 journal VDB I:(DE-2719)1110002 UNRESTRICTED